Repros Therapeutics Inc. Press Releases

RPRX 
$8.79
*  
0.19
2.12%
Get RPRX Alerts
*Delayed - data as of Nov. 21, 2014  -  Find a broker to begin trading RPRX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
11/10/2014 9:00:00 AM - GlobeNewswire


Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
11/6/2014 4:15:00 PM - GlobeNewswire


Repros to Webcast Investor and Analyst Day on October 31st
10/27/2014 4:01:00 PM - GlobeNewswire


Results From Long-Term Study of Androxal(R) Exhibit Positive Safety Profile
10/21/2014 4:01:00 PM - GlobeNewswire


INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
10/17/2014 8:28:00 PM - PR Newswire
▲39.08 % Price Change since this news event. The Volume Ratio is 0.74.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX
10/17/2014 12:11:00 PM - PR Newswire


Upcoming FDA Meeting to be Type C Meeting
10/16/2014 8:01:00 PM - GlobeNewswire


FDA Schedules Type B Pre-NDA Meeting With Repros
9/26/2014 6:45:00 AM - GlobeNewswire


Androxal(R) Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints Versus Marketed Topical Gel in the Treatment of Secondary Hypogonadism
9/25/2014 8:20:00 PM - GlobeNewswire


Repros Gives Update on Androxal(R) With Respect to Recent FDA Advisory Panel Outcome and Announces Upcoming Presentation at Biocentury
9/22/2014 9:15:00 AM - GlobeNewswire


Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism
8/27/2014 8:10:00 PM - GlobeNewswire